cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/pr00006654.0
title: Available IPD datapackage for study 'A Randomized, Multicenter, Open-Label, Two-Arm, Phase III Neoadjuvant Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Breast Cancer'

description: This is a randomized, multicenter, open-label, two-arm study in treatment-naive participants with operable, locally advanced, or inflammatory, centrally-assessed HER2-positive early breast cancer (EBC) whose primary tumors were greater than or equal to (>/=) 2 centimeters (cm). The study was designed to evaluate the efficacy and safety of trastuzumab emtansine + pertuzumab (experimental arm; T-DM1 + P) versus chemotherapy, trastuzumab + pertuzumab (control arm; TCH + P). The study comprised a neoadjuvant treatment period, followed by surgery, and an adjuvant treatment period. Treatment can be stopped due to disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination.
DOI: 10.25934/pr00006725.0
title: Available IPD datapackage for study 'A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy'

description: This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6 mg/kg or trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles. Radiotherapy and/or hormone therapy will be given in addition if indicated.
DOI: 10.25934/pr00007152.0
title: Available IPD datapackage for study 'A Phase 1, Multicenter, Open-label, Single Sequence Crossover Study to Evaluate Drug-drug Interaction Potential of OATP1B/CYP3A Inhibitor on the Pharmacokinetics of DS-8201a in Subjects With HER2-expressing Advanced Solid Malignant Tumors'

description: HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells. This study will test an experimental drug called DS-8201a that has not been approved by the health authorities yet. DS-8201a will be tested for safety in patients with advanced solid malignant tumors that test positive for HER2. It also will test how DS-8201a moves within the body (pharmacokinetics).
DOI: 10.25934/00006958
title: Long-term placebo-controlled double-blind parallel-group study of corticosteroid treatment in patients with stage I and stage II newly detected pulmonary sarcoidosis. A Finnish multicenter study performed by members of the Finnish Association of Chest Physicians

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00005636.0
title: Available IPD datapackage for study 'A multinational open-label study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2lneu overexpression who have relapsed following one or two cytotoxic chemotherapy regimens for metastatic breast cancer.'

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00005637.0
title: Available IPD datapackage for study 'A multinational randomized single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2lneu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer.'

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00005638.0
title: Available IPD datapackage for study 'An open-label extension study with recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) for patients whose metastatic breast cancer progressed during treatment on protocol H0648g.'

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00005752.0
title: Available datapackage for study 'An Open-Label, Multi-Center Phase I/II Study of the Safety and Tolerability of the Combination of Trastuzumab-MCC-DM1 (T-DM1) With Docetaxel, and Potentially Pertuzumab, for Treatment for Patients With Advanced Breast Cancer'

description: This is an open-label, multi-center, non-randomized study of the safety and tolerability of the combination of T-DM1 plus docetaxel for the treatment of participants with metastatic breast cancer (MBC) and of T-DM1 plus docetaxel with or without pertuzumab, for the treatment of participants with locally advanced breast cancer (LABC). The study comprises an initial dose finding (feasibility) part to determine the maximum tolerated dose (MTD) of T-DM1 and docetaxel, followed by an extension part aiming to consolidate the safety and efficacy of the recommended docetaxel/T-DM1 combination regimen.
DOI: 10.25934/pr00005753.0
title: Available datapackage for study 'A Phase II, Open-Label Study to Evaluate Corrected QT Interval Effects of Trastuzumab-MCC-DM1 (T-DM1) in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer and to Evaluate the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression While Receiving T-DM1 Alone'

description: This is a multicenter, open-label, single-arm Phase II study designed to evaluate the effect of T-DM1 on the duration of corrected QT (QTc) interval in patients with HER2-positive locally advanced or metastatic breast cancer and to make preliminary assessments regarding the safety, tolerability, and efficacy of combined T-DM1 and pertuzumab in patients with early disease progression. The QT interval is a measure of time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. The QTcF interval is the QT interval as calculated using Fridericia's correction; the QTcB interval is the QT interval as calculated using Bazett's correction.
DOI: 10.25934/pr00006653.0
title: Available IPD datapackage for study 'A Multicenter Randomized Phase III Study to Compare the Combination Trastuzumab and Capecitabine, With or Without Pertuzumab, in Patients With HER2-Positive Metastatic Breast Cancer That Have Progressed After One Line of Trastuzumab-Based Therapy in the Metastatic Setting (PHEREXA)'

description: This randomized, two-arm study evaluated the efficacy and safety of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The study population consisted of female patients, whose disease had progressed during or following previous trastuzumab therapy for metastatic disease. All patients in Arm A and Arm B received trastuzumab (8 mg/kg iv as loading dose and then 6 mg/kg iv every 3 weeks thereafter) and capecitabine oral twice daily for 14 days every 3 weeks (1250 mg/m2 twice daily in Arm A and 1000 mg/m2 twice daily in Arm B). In addition, patients in Arm B received pertuzumab (840 mg iv as loading dose and then 420 mg iv thereafter) every 3 weeks. Study treatment continued until disease progression or unacceptable toxicity.
DOI: 10.25934/pr00007611.0
title: Available IPD datapackage for study 'A Multicenter, Multinational, Phase II Study to Evaluate Perjeta in Combination With Herceptin and Standard Neoadjuvant Anthracycline-Based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer'

description: This multicenter, non-randomized, open-label, phase 2 study is designed to evaluate the safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and anthracycline-based chemotherapy as neoadjuvant treatment in participants with HER2-positive locally advanced, inflammatory, or early-stage breast cancer. Each investigator will choose a treatment regimen (A or B) for all of their participants to follow. Treatment regimen A (for Cohort A) will include dose-dense doxorubicin and cyclophosphamide (ddAC), followed by paclitaxel, with pertuzumab and trastuzumab given from the start of paclitaxel. Treatment regimen B (for Cohort B) will include 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), followed by docetaxel, with pertuzumab and trastuzumab given from the start of docetaxel. Participants in both cohorts will subsequently undergo surgical treatment and then resume pertuzumab and trastuzumab treatment.
DOI: 10.25934/00002921
title: Safety and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to HIV-positive Adults Living in a Tuberculosis Endemic Region

description: The purpose of the study is to assess the safety and immunogenicity of a GlaxoSmithKline (GSK) Biologicals' candidate tuberculosis vaccine (692342) administered to Human Immunodeficiency Virus (HIV)-positive adults aged 18 to 59 years, living in a tuberculosis endemic region. Subjects will be followed-up for 3 years. Subjects will be enrolled in 3 cohorts:   -  HIV-positive adults on highly active antiretroviral therapy   -  HIV-positive adults not on highly active antiretroviral therapy   -  HIV-negative adults Each cohort will have 2 groups.
DOI: 10.25934/00003691
title: Effect of a 12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe COPD Patients. Correlation to Dyspnoea Scales. A Double-blind, Placebo-controlled, Randomized, Parallel Group Study

description: Determine the effect of 12-week treatment with inhaled tiotropium bromide on lung function and static lung volumes, correlate this effect with dyspnoea in COPD patients.
DOI: 10.25934/00005225
title: Long Time Survey of RESPIMAT in Daily Clinical Use

description: To investigate safety and effectiveness information on the use of Tiotropium Respimat for long time of period in daily practical clinical circumstances, and to obtain proper drug use information.
DOI: 10.25934/pr00004517.0
title: Available IPD datapackage for study 'A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Parallel-Design Study to Evaluate the Short-Term, Fixed Dose Efficacy and Safety of LY110140 Once Daily Dosing in Japanese Patients With Major Depressive Disorder'

description: The purpose of this study is to evaluate the short-term efficacy and safety of Fluoxetine in Japanese adult participants with Major Depressive Disorder (MDD).
DOI: 10.25934/pr00005641.0
title: Available IPD datapackage for study 'An open-label, randomized phase II study of Herceptin (trastuzumab), Taxotere (docetaxel) and Xeloda (capecitabine) in combination, versus Herceptin (trastuzumab) plus Taxotere (docetaxel), in patients with advanced and/or metastatic breast cancers that overexpress HER2.'

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00005649.0
title: Available IPD datapackage for study 'A Randomized, Open-label Study of the Effect of Herceptin Plus Arimidex Compared With Arimidex Alone on Progression-free Survival in Patients With HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer'

description: This 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (Herceptin®) to daily oral anastrozole (Arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal growth factor receptor-2 (HER2) overexpressing metastatic breast cancer (ER+ve and/or PR+ve). Patients were randomized to receive either anastrazole 1 mg per os (po) daily, or anastrazole 1 mg po daily + a loading dose of Herceptin® 4 mg/kg intravenous (iv) followed by weekly doses of Herceptin® 2 mg/kg iv. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.
DOI: 10.25934/pr00006059.0
title: Available IPD datapackage for study 'A Two-Cohort, Open-Label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-Based Treatment'

description: This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior anti-HER2 and chemotherapy-based treatment. Participants in Cohort 1 will be drawn from the general participant population; Cohort 2 will include only Asian participants.
DOI: 10.25934/pr00007259.0
title: Available IPD datapackage for study 'A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis'

description: This study was designed to evaluate if subjects who achieve complete remission after 8 weeks of acute therapy with MMX mesalamine/mesalazine 4.8g/day given QD have better long-term outcomes and remain in remission longer compared with subjects who demonstrate only partial remission after acute therapy with MMX mesalamine/mesalazine 4.8g/day given QD. Therefore, subjects who achieve either complete or partial remission will enter into a 12-month maintenance phase, during which they will receive MMX mesalamine/mesalazine 2.4g/day given QD. Remission status for the 2 groups will be evaluated and compared at the end of this 12-month maintenance period. The data obtained from this study will provide scientifically meaningful information to demonstrate that achieving complete remission (clinical and endoscopic remission) is important for a better long-term prognosis, or that the current paradigm of symptomatic treatment is appropriate.
DOI: 10.25934/pr00008382.0
title: Available datapackage for study 'An Extension Study of ABBV-8E12 in Early Alzheimer's Disease'

description: The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with early AD.
DOI: 10.25934/pr00008678
title: Long-term Study of DSP-5423P in Patients With Schizophrenia <Phase 3>

description: The study evaluates the long term safety of DSP-5423P in patients with schizophrenia.
DOI: 10.15468/dl.teqgk3
title: Occurrence Download

description: A dataset containing 733 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Machaeranthera pinnatifida (Hook.) Shinners",
 "Geometry POLYGON((-141 24, -53 24, -53 83, -141 83, -141 24))"
 ]
}

 The dataset includes 733 records from 51 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012502-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.227p3f
title: Occurrence Download

description: A dataset containing 329 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Ovalipes punctatus (De Haan, 1833)",
 "Geometry POLYGON((170 20, 170 50, 120 50, 120 20, 170 20))",
 "HasCoordinate is true"
 ]
}

 The dataset includes 329 records from 11 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012505-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.rra4ny
title: Occurrence Download

description: A dataset containing 2123 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Lippia javanica (Burm.f.) Spreng."
 ]
}

 The dataset includes 2123 records from 63 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012503-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.57760/sciencedb.psych.00683
title: The Narrowing Self: Depressive Tendency Attenuates the Mother Reference Effect
title: 自我概念的收缩：抑郁倾向削弱母亲参照效应

description: This dataset contains the experimental data from the study titled "The Narrowing Self: Depressive Tendency Attenuates the Mother Reference Effect." In Experiment 1, 65 participants were initially selected through a screening scale, but one participant was excluded due to keypress errors, leaving 64 participants for analysis. This includes 32 participants with low depressive proneness (6 males, 27 females; M = 22.16 years, SD = 1.92) and 32 participants with high depressive proneness (10 males, 22 females; M = 20.87 years, SD = 1.52). In Experiment 2, a final sample of 60 participants was confirmed. Among them, there were 29 participants with low depressive proneness (6 males, 23 females; M = 20.17 years, SD = 1.34) and 31 participants with high depressive proneness (6 males, 26 females; M = 20.23 years, SD = 1.34). For Experiment 3, a total of 64 participants took part in the experiment. Two participants were excluded due to excessive EEG artifacts, and another two were excluded because their depression scores before and after the experiment were inconsistent, resulting in a final sample of 60 participants. This includes 30 participants in the low depressive proneness group (5 males, 25 females; M = 20.70, SD = 2.39) and 30 participants in the high depressive proneness group (8 males, 22 females; M = 20.30, SD = 1.56).
description: This dataset contains the experimental data from the study titled "The Narrowing Self: Depressive Tendency Attenuates the Mother Reference Effect." In Experiment 1, 65 participants were initially selected through a screening scale, but one participant was excluded due to keypress errors, leaving 64 participants for analysis. This includes 32 participants with low depressive proneness (6 males, 27 females; M = 22.16 years, SD = 1.92) and 32 participants with high depressive proneness (10 males, 22 females; M = 20.87 years, SD = 1.52). In Experiment 2, a final sample of 60 participants was confirmed. Among them, there were 29 participants with low depressive proneness (6 males, 23 females; M = 20.17 years, SD = 1.34) and 31 participants with high depressive proneness (6 males, 26 females; M = 20.23 years, SD = 1.34). For Experiment 3, a total of 64 participants took part in the experiment. Two participants were excluded due to excessive EEG artifacts, and another two were excluded because their depression scores before and after the experiment were inconsistent, resulting in a final sample of 60 participants. This includes 30 participants in the low depressive proneness group (5 males, 25 females; M = 20.70, SD = 2.39) and 30 participants in the high depressive proneness group (8 males, 22 females; M = 20.30, SD = 1.56).
DOI: 10.57760/sciencedb.psych.00676
title: Effect of Algorithmic Incentive on the Work Well-being of Civil Servants
title: 工作员工作幸福感的算法激励效应研究

description: The rapid advancement of artificial intelligence (AI) technology has driven government organizations to widely adopt algorithmic tools in human resource management decision-making. However, existing research has yet to reach a consensus on the effectiveness of algorithmic decision-making, and there remains a lack of exploration into its relationship with civil servants’ work-related well-being in incentive contexts. Grounded in social information processing theory, this study constructs a theoretical model to examine how algorithmic decision-making influences civil servants’ work well-being, employing a mixed-method approach combining scenario-based experiments and critical incident techniques. The findings reveal that algorithmic HRM decisions significantly enhance organizational fairness perceived by civil servants, thereby improving their work well-being. Work meaningfulness serves as a moderator in this process, amplifying the positive effect of organizational fairness on well-being when work meaningfulness is high. This study not only expands the theoretical boundaries of algorithmic decision-making in the public sector but also offers policy insights for governments to optimize digital management and incentive practices for civil servants.
description: The rapid advancement of artificial intelligence (AI) technology has driven government organizations to widely adopt algorithmic tools in human resource management decision-making. However, existing research has yet to reach a consensus on the effectiveness of algorithmic decision-making, and there remains a lack of exploration into its relationship with civil servants’ work-related well-being in incentive contexts. Grounded in social information processing theory, this study constructs a theoretical model to examine how algorithmic decision-making influences civil servants’ work well-being, employing a mixed-method approach combining scenario-based experiments and critical incident techniques. The findings reveal that algorithmic HRM decisions significantly enhance organizational fairness perceived by civil servants, thereby improving their work well-being. Work meaningfulness serves as a moderator in this process, amplifying the positive effect of organizational fairness on well-being when work meaningfulness is high. This study not only expands the theoretical boundaries of algorithmic decision-making in the public sector but also offers policy insights for governments to optimize digital management and incentive practices for civil servants.